drugset
Drugs / ALN-TTRSC
last change Oct 2016 re-read 3 minutes ago

ALN-TTRSC

also known as revusiran
Investigated by
Alnylam Pharmaceuticals

Trials 1

today NCT01981837 · Ph 2
20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT01981837 Dec 2013 → Oct 2014 — Alnylam Pharmaceuticals Completed No outcome recorded
Comparator or background therapy1 trial
Phase 1 NCT01814839 Comparator Mar 2013 → Apr 2015 — Alnylam Pharmaceuticals Completed No outcome recorded

Press releases naming this drug 15 releases

DateIssuerRelease
2016-10-05 Alnylam Pharmaceuticals Alnylam Pharmaceuticals Discontinues Revusiran Development alnylam.com ↗
2016-08-08 Alnylam Pharmaceuticals Alnylam Completes Enrollment in ENDEAVOUR Phase 3 Study with Revusiran, an Investigational RNAi Therapeutic for Patients with Hereditary ATTR Amyloidosis with Cardiomyopathy (hATTR-CM) alnylam.com ↗
2016-06-27 Alnylam Pharmaceuticals Alnylam to Report New Patisiran and Revusiran Results at the XV International Symposium on Amyloidosis alnylam.com ↗
2015-11-03 Alnylam Pharmaceuticals Alnylam Reports Positive Results from Ongoing Phase 2 Open-Label Extension (OLE) Studies for Patisiran and Revusiran, in Development for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) alnylam.com ↗
2015-05-20 Alnylam Pharmaceuticals Alnylam Receives Orphan Drug Designation from the United States Food & Drug Administration for Revusiran, an Investigational RNAi Therapeutic for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) alnylam.com ↗
2015-03-15 Alnylam Pharmaceuticals Alnylam Presents Results from Natural History Study of Patients with Familial Amyloidotic Cardiomyopathy (FAC) and Presents Complete Results from Phase 2 Clinical Trial for Revusiran, an Investigational RNAi Therapeutic for the Treatment of FAC alnylam.com ↗
2014-12-11 Alnylam Pharmaceuticals Alnylam Initiates ENDEAVOUR Phase 3 Clinical Trial with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis alnylam.com ↗
2014-11-14 Alnylam Pharmaceuticals Alnylam Announces Positive Initial Phase 2 Data with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis, with up to 98.2% Knockdown of Serum TTR in Patients alnylam.com ↗
2014-11-05 Alnylam Pharmaceuticals Alnylam Completes Phase 2 Enrollment and Initiates Open-Label Extension (OLE) Study with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis alnylam.com ↗
2014-04-02 Alnylam Pharmaceuticals Alnylam Receives Positive Opinion for Orphan Drug Designation in the European Union for ALN-TTRsc, a Subcutaneously Delivered RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis (ATTR) alnylam.com ↗
2013-12-16 Alnylam Pharmaceuticals Alnylam Initiates Phase II Clinical Trial with ALN-TTRsc, a Subcutaneously Delivered RNAi Therapeutic Targeting Transthyretin (TTR) in Development for the Treatment of TTR-Mediated Amyloidosis (ATTR) alnylam.com ↗
2013-09-23 Alnylam Pharmaceuticals Alnylam Reports Positive Clinical Results — with up to 94% Knockdown of Serum Transthyretin (TTR) — for ALN-TTRsc, a Subcutaneously Delivered RNAi Therapeutic for the Treatment of TTR-Mediated Amyloidosis (ATTR) alnylam.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as ALN-TTRSC ClinicalTrials.gov intervention name — accepted as the source's own label NCT01814839 ↗
1

NCT01981837 ↗
Known as revusiran “ALN-TTRSC (revusiran) for subcutaneous administration” NCT01981837 ↗
1

“ALN-TTRSC (revusiran)” NCT01814839 ↗
Route Subcutaneous “by subcutaneous (SC) injection” NCT01814839 ↗